Physician profile
Chandra Lea Hendrix
NPI 1689132508
$7,096.40
in general payments reported to CMS, 2019-2025
27 companies · $880 in 2025
The $880 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2021: $669 · 2022: $736 · 2023: $1,622 · 2024: $2,970 · 2025: $880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,290 · Travel and Lodging: $1,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,289.69 |
| Travel and Lodging | $1,182.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,518.73 | 2023-2025 | Cardiomems, Advisor, Ensite |
| Boston Scientific Corporation | $1,113.03 | 2019-2025 | Watchman Flx, Watchman Access System, Bodyguardian |
| Astrazeneca Pharmaceuticals LP | $499.74 | 2021-2025 | Wainua, Farxiga |
| Medtronic, INC. | $450.77 | 2022-2024 | Corevalve Evolut R, Endurant Iis |
| Cvrx, INC. | $400.90 | 2023-2025 | Barostim Neo System |
| Amgen INC. | $385.89 | 2021-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $254.75 | 2023-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $223.56 | 2023-2025 | Verquvo, Steglatro, Steglujan |
| Sanofi-Aventis U.S. LLC | $186.14 | 2022-2024 | |
| Impulse Dynamics (USA) INC. | $154.60 | 2022-2023 | Optimizer |
| Novo Nordisk INC | $127.89 | 2024-2025 | Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $105.62 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $98.93 | 2024 | Eliquis, Camzyos |
| Esperion Therapeutics, INC. | $71.02 | 2023-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.31 | 2023-2024 | Jardiance, Tradjenta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $60.35 | 2022-2025 | |
| Bridgebio Pharma, INC. | $51.38 | 2025 | Attruby |
| Abbvie INC. | $48.86 | 2024 | |
| Janssen Pharmaceuticals, INC | $46.50 | 2023-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $45.01 | 2024 | Opsumit, Uptravi |
| Endologix LLC | $44.89 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.92 | 2022-2025 | |
| Biosense Webster, INC. | $34.11 | 2023 | Carto 3 |
| Kestra Medical Technology Services, INC. | $27.41 | 2025 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $18.13 | 2024 | Arcalyst |
| Lilly USA, LLC | $17.65 | 2023 | Baqsimi, Jardiance |
| Cardiovascular Systems INC. | $6.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandra Hendrix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.